Abstract. Aortopathy represents an important cause of mortality in industrialized countries, with a number of genes identified as predispose factors. It can be difficult to identify the genetic lesions underlying this disorder, particularly when the phenotype is atypical. The present study performed targeted next-generation sequencing of 428 genes associated with cardiovascular diseases in a family with aortopathy, the proband of which presented with abdominal aortic aneurysm rupture only, with tissue fragility noted in surgery. After targeted capture, sequencing and bioinformatics analysis, a missense mutation, p.A1259T, was identified in the collagen type III α1 (COL3A1) gene and co-segregated with the disease in the family. Crystal structure modeling revealed abnormal hydrogen bonds generated by the mutation, which likely affected the spatial structure of the procollagen C-propeptide. Mutations in the procollagen C-propeptide are rare and genotype-phenotype correlation may explain the atypical manifestations of affected individuals. The results of the present study suggested that targeted gene capture combined with next-generation sequencing can serve as a useful technique in the genetic diagnosis of aortopathy, particularly in the content of an atypical phenotype.
Introduction
Aortopathy, predominantly manifested as aortic aneurysm and dissection, represents an important cause of mortality in industrialized countries. An estimated 20% of patients with aortopathy have a positive family history, indicating a genetic predisposition to the disease (1) . Genetics-associated aortopathy can be divided into syndromic and non-syndromic subgroups, depending on the presence or absence of manifestations in other organ systems. Well-characterized syndromic forms with aortic involvement include Marfan syndrome (OMIM 154700), vascular Ehlers-Danlos syndrome (vEDS; OMIM 130050), Loeys-Dietz syndrome (OMIM 609192) and aneurysms-osteoarthritis syndrome (OMIM 613795) (2) . When an underlying gene defect is suspected to be responsible for aortopathy, identifying the causative gene is critical for patient management and genetic counseling of the family (3) . Affected individuals can benefit from interval screening and timely intervention.
Familial aortopathy is an autosomal dominant condition with significant genetic heterogeneity, and mutations in >12 genes have been identified to account for the disorder (4) . Conventional methods to identify genes underlying aortopathy depend primarily on genotype-phenotype correlation. For example, patients with ocular, skeletal and cardiovascular abnormalities are often found to harbor fibrillin 1 (1) mutations. However, the clinical manifestations vary substantially, ranging from mild to severe systemic disease (5) . In addition, a significant overlap of clinical features has been observed in patients with aortopathy caused by different genes (6) . As a result, Sanger sequencing of all candidate genes is required to provide a molecular diagnosis, however, the procedure is laborious and time consuming. The targeted next-generation sequencing method allows for the simultaneous assessment of multiple genes of interest and can be an efficient approach to identify the genes underlying inherited aortopathy in individuals.
Pilot investigations investigating the utilization of this method in the molecular diagnosis of patients with aortopathy have shown promising results (7, 8 
Materials and methods
Ethics statement and subjects. The present study was performed in accordance with the review board of Nanjing Drum Tower Hospital (Nanjing, China), and written informed consent was obtained from all study subjects. All procedures were performed according to the tenets of the Declaration of Helsinki. The subjects included in the present study comprised a non-consanguineous Han Chinese family with suspected inherited aortopathy from Jiangsu, China (Fig. 1A) . The index case (II:1; proband) was a 48-year-old woman with a ruptured abdominal aortic aneurysm (Fig. 1B) , who underwent emergency surgery for repair. During vascular prostheses replacement, blood vessel friability was noted and the procedure duration was twice that estimated. The patient developed renal failure due to this extended duration of surgery. Clinical examination revealed no pronounced craniofacial, skeletal or skin anomalies. The patient also denied any tendency to bruise. The proband's sister (II:3) reported a similar disease experience at the age of 50 years. Her mother (I:2) succumbed to mortality suddenly at the age of 52 years of an unknown cardiovascular cause. Peripheral blood (2 ml) was collected in EDTA-coated tubes from available family members and stored at -80˚C. Genomic DNA was extracted using standard protocols. As a control group, 100 unrelated, ethnically-matched, healthy individuals were recruited at the Center of Physical Examination of Nanjing Drum Tower Hospital.
Illumina library construction. Genomic DNA was purified and quantified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The generation of a targeted Illumina library was performed according to the manufacture's protocol (MyGenostics, Inc., Beijing, China). A final library size of 350-400 bp including adaptor sequencings was selected.
Targeted capture, sequencing and bioinformatics analysis.
A panel of 428 genes associated with cardiovascular diseases, including 12 known disease-causing genes [FBN1, EGF-containing fibulin-like extracellular matrix protein 2, collagen type III α1 (COL3A1), transforming growth factor β (TGFB) receptor 1, TGFB receptor 2, TGFB2, TGFB3, small mothers against decapentaplegic (SMAD) 3, SMAD4, actin α2 smooth muscle aorta, myosin heavy chain 11 and mysosin light chain kinase], were selected using a gene capture strategy with the GenCap custom enrichment kit (MyGenostics, Inc), as previously described (9) . The enriched libraries were sequenced on an Illumina Solexa HiSeq 2000 sequencer for 100-paired reads.
Following sequencing, high-quality reads were retrieved from raw reads by filtering out low-quality reads and adaptor sequences using the Solexa QA package (10) and Cutadapt program (http://code.google.com/p/cutadapt/), respectively. Short Oligonucleotide Analysis Package (SOAP) aligner software (SOAP2.21; soap.genomics.org.cn/soapsnp.html) was then used to align the clean reads to the reference human genome (hg19) (11) . Polymerase chain reaction (PCR) duplicates were removed using the Picard program (12) . Subsequently, single nucleotide polymorphisms (SNPs) were determined using the SOAPsnp program (11), reads were realigned using Burrows-Wheeler Aligner (13) , and the deletions and insertions (InDels) were detected using Genome Analysis Toolkit software (14) . The identified SNPs and InDels were annotated using the Exome-assistant program (http://122.228.158.106/exomeassistant). MagicViewer was used to view the short read alignment, and confirm the candidate SNPs and InDels (15) . Non-synonymous variants were evaluated using the four algorithms, PolyPhen (http://genetics. bwh.harvard.edu/pph2/), Sorting Intolerant From Tolerant [SIFT; (http://sift.jcvi.org/)], Protein Analysis Through Evolutionary Relationships (PANTHER; www.pantherdb.org) and Pathogenic Mutation Prediction (Pmut; http://mmb.pcb. ub.es/PMut/) to determine pathogenicity (16) .
Mutation validation and analysis. Genomic DNA from all available family members were obtained for Sanger sequencing. The PCR samples were visualized on agarose gels, purified and sequenced on an ABI PRISM 3730 genetic analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the terminator cycle sequencing method. Sites of variation were identified through a comparison of DNA sequences with the corresponding GenBank (www.ncbi. nlm.nih.gov) reference sequences. Possible pathogenic effects caused by the rare or novel non-synonymous SNPs were evaluated using SIFT, PolyPhen2 and MutationTaster (http://www.mutationtaster.org/). Multiple sequence alignments were performed using ClustalW2 with the default setting (http://www.ebi.ac.uk/Tools/clustalw2/).
Structure analysis. The 3D structure of the procollagen III C-propeptide (Protein Data Bank; www.rcsb.org/pdb/; reference, 4AE2) was used to perform in silico analysis. The crystal structures of the mutant proteins were predicted using the SWISS-MODEL online server (17) and displayed using PyMol software (version 1.5; www.pymol.org).
Results
Targeted next-generation sequencing. The present study performed targeted capture and next-generation sequencing of 428 genes implicated in cardiovascular diseases. The average sequencing depth for the targeted regions was ~328X. The sample had 93.40% coverage of the targeted regions. There was 91.20 and 87.50% coverage of the targeted exons for 10X and 20X, respectively. A total of 782 variants were identified in the sample. Among these, 394 missense, nonsense, splicing variants and coding InDels were identified, which more likely to be pathogenic. This was narrowed down to 41 by excluding variants reported in the dbSNP138 (www.ncbi.nlm.nih. gov/SNP/), 1000 Genomes Project (www.1000genomes.org), Exome Sequencing Project (evs.gs.washington.edu/EVS/) and local dataset with allele frequencies >0.01. This was further narrowed down to 15 by filtering benign variants predicted the by four algorithms, PolyPhen, SIFT, PANTHER and Pmut. A missense variant, c.3775G>A (p.A1259T) in exon 48 of COL3A1 (NM_000090), was most likely disease-causing in this family, as the mutated gene is known to be involved in inherited aortopathy (Table I) . For this site, 51% (193/377) reads supported for G, whereas 49% (184/377) reads supported for A.
Mutation validation. To confirm the above findings, the present study genotyped four available members of the family (two affected, two unaffected) to identify the c.3775G>A (p.A1259T) variant by Sanger sequencing (Fig. 2A) . The affected individuals (II:1 and II:3) were found to harbor the mutation, suggesting cosegregation of the mutation with development of the disease. The sequencing results of those unaffected (I:1 and II:2) excluded the presence of the mutation, suggesting that the mutation may have been inherited from the proband's affected mother.
The variant occurred in a conserved amino acid (Fig. 2B) , and was predicted to have a functional effect by SIFT, PolyPhen2 and MutationTaster. In addition, the mutation was not found on the 200 unrelated chromosomes from ethnically matched controls.
Structure analysis. The altered residue was located in the procollagen C-propeptide region, the stability of which is crucial in procollagen assembly. The missense mutation resulted in a substitution of hydrophobic alanine by hydrophilic threonine at a conserved site. Structure modeling demonstrated the generation of a novel hydrogen bond between the mutated threonine at residue 1,259 and asparagine at residue 1,261 (Fig. 3) . This was likely to alter the spatial conformation of the region, thus leading to production of abnormal protein.
Discussion vEDS is a rare autosomal dominant disorder of connective tissue owing to mutations of the COL3A1 gene encoding type III procollagen, resulting in deficiency of collagen III protein (18) . Type III collagen is a major component of the skin, blood vessels and hollow organ walls. This explains why patients affected by vEDS are at increased risk of vascular, intestinal or uterine rupture (19, 20) . Due to these life-threatening complications, the survival rates of affected patients are significantly reduced. The first major complication, namely vascular or internal organ rupture, occurs in 25% of patients by the age of 20 years and in >80% of patients by the age of 40 years, with a median survival duration of 48 years (19) . Therefore, early diagnosis is necessary for timely precaution measures to avoid such outcomes. Currently, vEDS is diagnosed on the basis of the presence of at least two of the following major diagnostic criteria: Characteristic facial appearance, tendency to bruise easily, translucent skin with visible veins, history of arterial, intestinal or uterine rupture. Collagen protein analysis of cultured fibroblasts or identification of mutations in the COL3A1 gene is required to achieve an ultimate diagnosis. The proband in the present study presented with minimal signs of vEDS, precluding from performing direct sequencing of the COL3A1 gene. In accordance with previously published data, the present study further supported that vEDS is a heterozygous disease with marked variability of clinical manifestations (21,22). To date, >700 COL3A1 mutations have been identified in vEDS cohorts (23) . Almost two thirds of the mutations are heterozygous missense substitutions affecting one of the glycine residues of the (Gly-X-Y) repeat within the triple helical domain. One third of the mutations are spice-site variants causing exon skipping. These two types of mutations act in a dominant-negative manner, resulting in abnormal procollagen peptide production. The remaining COL3A1 mutations are nonsense or frameshift mutations, which cause premature termination of translation, leading to haplo-insufficiency of normal protein. Haplo-insufficiency mutations have been reported to delay the onset of complications and increase life expectancy, compared with dominant-negative mutations (24, 25) . Despite the wide distribution regarding COL3A1 mutations, variants affecting the C-propeptide region are rare. Frank et al (26) previously categorized COL3A1 variants into five groups: i) Glycine substitutions, ii) splice-site and in-frame insertions-deletions, iii) variants leading to haplo-insufficiency, iv) non-glycine missense variants within the triple helix and v) non-glycine missense variants or in-frame InDels in the N-or C-terminal of the protein (26) . It was found that patients with variants leading to haplo-insufficiency, non-glycine missense variants within the triple helix or non-glycine missense variants or in-frame InDels in the N-or C-terminal of the protein had a less typical phenotype and prominent absence of digestive complication. In line with these observations, the complication of the proband in the present study occurred at relatively late age and was limited entirely to vascular events. These findings provided further evidence that COL3A1 mutations located in the C-termini had a milder course of the disease and fewer characteristic features.
Due to the absence of prevalent diagnostic criteria for patients with vEDS, individuals harboring this specific type of mutation are unlikely to undergo genetic analysis in clinical settings. This explains the scarcity of mutations reported in the C-propeptide region. Previously, targeted region capture combined with next-generation sequencing was successfully utilized to uncover pathologic variants of COL3A1 in individuals with aortopathy with unsuspected vEDS (7, 27) . As with the proband in the present study, they were subject to targeted sequencing primarily based on aortic phenotypes, rather than other syndromic manifestations. They did not present with the skin or facial features characteristic of vEDS. Therefore, targeted next-generation sequencing has been suggested as a useful diagnostic tool in patients with arotopathy, particularly in those with an absence of characteristic phenotypes. Of note, one patient was found to have unusual tissue fragility in the previous study, which aligned with the findings of the present study and several previous studies (22, 28) . Tissue fragility may be a consequence of collagen abnormality, indicating the presence of mutations in genes encoding collagen (22, 29) .
In conclusion, the present study identified a missense mutation in COL3A1 in a family with aortopathy by performing targeted next-generation sequencing. Despite the lack of characteristic vEDS manifestations, co-segregation analysis, the absence in public variation databases, conservation scores, bioinformatics prediction and alteration in crystal structure all provided support for the pathogenic role of the variant. The results of the present study suggested that targeted gene capture combined with next-generation sequencing serves as a useful technique in the genetic diagnosis of aortopathy, particularly in the content of atypical phenotype.
